Novel ultrasensitive detection device for early Sepsis diagnosis

Informations projet

IVD4Sepsis

N° de convention de subvention: 836153

DOI

10.3030/836153

Projet clôturé

Date de signature de la CE 21 Decembre 2018

Date de début 1 Janvier 2019

Date de fin 30 Avril 2019

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

MECWINS SA
Spain

Periodic Reporting for period 1 - IVD4Sepsis (Novel ultrasensitive detection device for early Sepsis diagnosis)

Période du rapport: 2019-01-01 au 2019-04-30

Résumé du contexte et des objectifs généraux du projet

Sepsis, defined as an extremely complex syndrome induced by infection, is a major public health concern according to the data of incidence, mortality and hospital costs reported. It remains a major cause of human disability and death throughout the world: it affects 30 million people worldwide every year (25% of sepsis patients die) and is the largest killer of children (around 82.000 every day; a death every three to four seconds). Accurate and early detection of sepsis remains a challenge.
Through the IVD4Sepsis project, Mecwins’ main objective is to bring to the market its proprietary AVAC technology as a reference technology for the detection of cytokine biomarkers, first for early sepsis diagnosis but with the ambition of later positioning it as the reference technology for a wide range of other clinical applications. IVD4Sepsis project will contribute to improve Sepsis diagnosis and therefore the survival rate of patients.
At the end of the project, IVD4Sepsis technology will meet the requirements of the sector and Mecwins will have the manufacturing capacity to cover the initial market penetration, creating important competitive technological and market advantages over future competitors, becoming a worldwide referent in offering analytical solutions in the diagnostic sector, first in the specific field of sepsis, but later extended to other critical illness fields such as oncology, cardiovascular diseases, autoimmune diseases and other infectious diseases than sepsis, such as HIV, meningitis.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

The objective of this Feasibility Study was to assess the feasibility of IVD4Sepsis project (Phase2) objectives, and to update the business innovation plan. As result of the Feasibility Study, a more detailed and reliable business innovation project aligned to MECWINS’s corporate strategy and with the customer needs has been elaborated.
Technical and financial viability of IVD4Sepsis has been validated:
- MECWINS's technology remains as the most feasible and effective beyond state of the art technologies currently available in the market.
- Nowadays, IVD4Sepsis does not have a critical competitor because a similar technology that offers such an advantageous performance has not been developed.
- As per result of IVD4Sepsis background and foreground IPR assessment, freedom to operate has been validated.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

IVD4Sepsis is really a high value proposal because is based on innovative technology but focused totally to respond the needs of the heath sector. Its technical specifications and characteristics have been designed specially to improve the current methods and instruments used nowadays having important impacts thanks to IVD4Sepsis accurate, fast, cost and simplicity.